Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q3

4587.TEDINET S100S80C
Period2023-01-01 → 2023-09-30
Filed2023-11-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥22.5bn2023-01-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥13.1bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥26.9bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥11.2bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.2bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥6.8bn2023-01-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥7.7bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income−¥427m2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.2bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥4.7bn2023-01-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥5.8bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥6.7bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥369m2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.2bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥3.5bn2023-01-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.3bn2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥187m2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥946m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥3.5bn2023-01-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥4.3bn2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥187m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥946m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥66.1bnat 2023-09-30Cons.Assets IFRS
Total assets¥63.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥51.3bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥28.6bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥31.8bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥37.5bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥24.5bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥37.5bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥32.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥24.5bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥13.6bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥4.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥9.2bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥83m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥1.4bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥1.8bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥27.4bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥27.0bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.9bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥20.8bn2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥20.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥27.32023-01-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥32.952023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥58.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-1.442022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥7.282022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥27.272023-01-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥32.912023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥58.142022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-1.442022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥7.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio56.7%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio47.7%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-09-30−¥63m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-09-30−¥63m
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥10.7bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥10.7bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-09-30¥6.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥11.9bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥11.8bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-09-30¥63m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-09-30¥247m
—segment totalrevenue2023-01-01 → 2023-09-30¥22.6bn
—segment totalrevenue external2023-01-01 → 2023-09-30¥22.5bn
—segment totalrevenue intersegment2023-01-01 → 2023-09-30¥63m
—segment totalsegment profit2023-01-01 → 2023-09-30¥6.8bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥8m
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥197m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥8m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30¥183m
—segment totalrevenue2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥8m
—segment totalsegment profit2022-01-01 → 2022-09-30−¥14m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 601
ItemContextValueUnit
Comprehensive income IFRSPrior1QuarterDuration-196963000JPY
Comprehensive income IFRSCurrentQuarterDuration6437249000JPY
Equity IFRSPrior2YearInstant_ShareCapitalIFRSMember3956738000JPY
Equity IFRSPrior2YearInstant_CapitalSurplusIFRSMember4452358000JPY
Equity IFRSPrior2YearInstant_TreasurySharesIFRSMember-620123000JPY
Equity IFRSPrior2YearInstant_RetainedEarningsIFRSMember16372687000JPY
Equity IFRSPrior2YearInstant_OtherComponentsOfEquityIFRSMember1188589000JPY
Equity IFRSPrior2YearInstant_EquityAttributableToOwnersOfParentIFRSMember25350250000JPY
Equity IFRSPrior2YearInstant25350250000JPY
Profit loss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-186603000JPY
Profit loss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember-186603000JPY
Profit loss IFRSPrior1YTDDuration-186603000JPY
Other comprehensive income IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember-709440000JPY
Other comprehensive income IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember-709440000JPY
Other comprehensive income IFRSPrior1YTDDuration-709440000JPY
Comprehensive income IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-186603000JPY
Comprehensive income IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember-709440000JPY
Comprehensive income IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember-896044000JPY
Comprehensive income IFRSPrior1YTDDuration-896044000JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember-87000JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember-87000JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration-87000JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember12956000JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember12956000JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration12956000JPY
Share based payment transactions ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember5502000JPY
Share based payment transactions ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember5502000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass